

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: <http://www.elsevier.com/locate/crvasa>

Guidelines

Summary of the 2014 ESC guidelines on non-cardiac surgery: Cardiovascular assessment and management

Prepared by the Czech Society of Cardiology[☆]



Hana Skalická^{a,*}, Zuzana Motoušková^b, František Toušek^c

^a Kardioambulace, s. r. o., Prague, Czech Republic

^b Third Medical Faculty of Charles University and University Hospital Royal Vineyards, Prague, Czech Republic

^c Kardiocentrum – Kardiologie, Nemocnice České Budějovice, a. s., Czech Republic

Authors of the original ESC document [1]. Steen Dalby Kristensen, Juhani Knuuti on behalf of the authors of the Joint Task Force of the non-cardiac surgery: Cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).

ARTICLE INFO

Article history:

Received 14 January 2015

Accepted 17 February 2015

Available online 30 March 2015

[☆] For permissions: please e-mail: guidelines@escardio.org.

* Corresponding author at. Cardiology, Kardioambulace s.r.o., Lovosická 40, 190 00 Praha 9, Czech Republic, Tel.: +420 266 010 275, fax: +420 266 010 285.

E-mail address: hanaskalicka@gmail.com (H. Skalická).

Abbreviations: AAA, abdominal aortic aneurysm; ACEI, angiotensin converting enzyme inhibitor; ACS, acute coronary syndromes; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMS, bare-metal stent; BNP, B-type natriuretic peptide; CABG, coronary artery bypass graft; CAS, carotid artery stenting; CEA, carotid endarterectomy; CMR, cardiovascular magnetic resonance; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CT, computed tomography; cTnI, cardiac troponin I; DAPT, dual anti-platelet therapy; DES, drug-eluting stent; ECG, electrocardiography/electrocardiographically/electrocardiogram; EVAR, endovascular abdominal aortic aneurysm repair; HF-PEF, heart failure with preserved left ventricular ejection fraction; ICD, implantable cardioverter defibrillator; IHD, ischaemic heart disease; INR, international normalized ratio; LMWH, low molecular weight heparin; LVEF, left ventricular ejection fraction; MET, metabolic equivalent; NOAC, non-vitamin K oral anticoagulant; NSTEMI-ACS, non-ST-elevation acute coronary syndromes; NT-proBNP, N-terminal pro-BNP; PAD, peripheral artery disease; PAH, pulmonary artery hypertension; PCC, prothrombin complex concentrate; PCI, percutaneous coronary intervention; SVT, supraventricular tachycardia; TAVI, transcatheter aortic valve implantation; TdP, torsades de pointes; TIA, transient ischaemic attack; TOE, transoesophageal echocardiography; UFH, unfractionated heparin; VHD, valvular heart disease; VKA, vitamin K antagonist; VPB, ventricular premature beat; VT, ventricular tachycardia.

<http://dx.doi.org/10.1016/j.crvasa.2015.02.008>

0010-8650/© 2015 European Society of Cardiology. All rights reserved. Published by Elsevier Sp.z.o.o. on behalf of the Czech Society of Cardiology.

Keywords:

Guidelines

Non-cardiac surgery

Pre-operative cardiac risk assessment

Pre-operative cardiac testing

Pre-operative coronary artery
revascularization

Perioperative cardiac management

Anti-thrombotic therapy

Beta-blockers

Anaesthesiology

Post-operative cardiac surveillance



ČESKÁ KARDIOLOGICKÁ SPOLEČNOST
THE CZECH SOCIETY OF CARDIOLOGY

Contents

1. Preamble	e192
2. Introduction	e192
2.1. The magnitude of the problem	e192
2.2. Purpose and organization.	e192
3. Pre-operative evaluation.	e193
3.1. Surgical risk for cardiac events	e193
3.2. Type of surgery.	e193
3.2.1. Endovascular vs. open vascular procedures	e193
3.2.2. Open vs. laparoscopic or thoracoscopic procedures.	e194
3.3. Functional capacity.	e194
3.4. Risk indices	e194
3.5. Biomarkers	e194
3.6. Non-invasive testing.	e195
3.6.1. Non-invasive testing of cardiac disease	e195
3.6.2. Non-invasive testing of ischaemic heart disease	e196
3.7. Invasive coronary angiography	e196
4. Risk-reduction strategies	e197
4.1. Pharmacological	e197
4.1.1. Beta-blockers	e197
4.1.2. Statins	e198
4.1.3. Nitrates	e198
4.1.4. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers	e198
4.1.5. Calcium channel blockers	e198
4.1.6. Alpha ₂ receptor agonists	e198
4.1.7. Diuretics.	e198
4.2. Perioperative management in patients on anti-platelet agents	e200
4.2.1. Aspirin	e200
4.2.2. Dual anti-platelet therapy.	e200
4.2.3. Reversal of anti-platelet therapy.	e200
4.3. Perioperative management in patients on anticoagulants	e200
4.3.1. Vitamin K antagonists.	e200
4.3.2. Non-vitamin K antagonist oral anticoagulants	e201
4.3.3. Reversal of anticoagulant therapy	e201
4.4. Revascularization	e203
4.4.1. Prophylactic revascularization in patients with asymptomatic or stable ischaemic heart disease	e203
4.4.2. Type of prophylactic revascularization in patients with stable ischaemic heart disease.	e203
4.4.3. Revascularization in patients with non-ST-elevation acute coronary syndrome	e204
5. Specific diseases	e204
5.1. Chronic heart failure	e204
5.2. Arterial hypertension	e204
5.3. Valvular heart disease	e204
5.3.1. Patient evaluation	e204

Download English Version:

<https://daneshyari.com/en/article/2728376>

Download Persian Version:

<https://daneshyari.com/article/2728376>

[Daneshyari.com](https://daneshyari.com)